SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Blue Jet Healthcare soars on commissioning multi- product Production block at Ambernath Unit 2 facility

01 Jul 2024 Evaluate

Blue Jet Healthcare is currently trading at Rs. 413.95, up by 10.00 points or 2.48% from its previous closing of Rs. 403.95 on the BSE.

The scrip opened at Rs. 400.05 and has touched a high and low of Rs. 425.00 and Rs. 400.05 respectively. So far 9565 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 438.00 on 21-Jun-2024 and a 52 week low of Rs. 319.40 on 12-Dec-2023.

Last one week high and low of the scrip stood at Rs. 425.00 and Rs. 394.40 respectively. The current market cap of the company is Rs. 7218.76 crore.

The promoters holding in the company stood at 86.00%, while Institutions and Non-Institutions held 5.04% and 8.96% respectively.

Blue Jet Healthcare has successfully completed commissioning of multi- product Production block to manufacture pharma intermediates at its existing Unit 2 facility situated at Ambernath, Maharashtra, India. The company has commenced manufacturing of Validation Batches with effect from June 29, 2024. The current capacity utilization is around 70% of the existing capacity. The company is proposed to commercialize full scale production within next six months. Total investment incurred is Rs 90 crore.

The Mumbai-based Blue Jet Healthcare is a specialty pharmaceutical and healthcare ingredient and intermediate company, offering niche products targeted towards innovator pharmaceutical companies and multinational generic pharmaceutical companies.


Blue Jet Healthcare Share Price

412.70 -10.15 (-2.40%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×